(Q37254387)

19 August 2017

0 references

1 reference

title

Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis (English)

1 reference

19 August 2017

main subject

arterial hypertension

0 references

meta-analysis

0 references

angiogenesis inhibitor

1 reference

1 reference

Xiaolei Zhu

1

1 reference

19 August 2017

Kathleen Stergiopoulos

series ordinal

2

1 reference

19 August 2017

Shenhong Wu

series ordinal

3

1 reference

19 August 2017

publication date

1 January 2009

1 reference

19 August 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

Acta Oncologica

1 reference

19 August 2017

volume

48

1 reference

19 August 2017

issue

1

1 reference

19 August 2017

page(s)

9-17

1 reference

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F02841860802314720

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802314720

The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802314720

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802314720

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802314720

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802314720

Sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802314720

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802314720

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802314720

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802314720

Quantitative synthesis in systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802314720

Controversies in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802314720

Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802314720

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802314720

Mechanisms of hypertension associated with BAY 43-9006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802314720

Limitations of creatinine as a filtration marker in glomerulopathic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802314720

Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802314720

Antagonism of the renin-angiotensin system can counteract cardiac angiogenic vascular endothelial growth factor gene therapy and myocardial angiogenesis in the normal heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802314720

Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802314720

Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860802314720

10.1080/02841860802314720

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference